glp-1 news today 2025 november 5 Novo Nordisk, Lilly strike deal with Trump to slash weight-loss drug prices GLP-1 Pipeline Update: November 2025

July 14, 2024: Ozempic Lawsuit Intensifies with New Studies Linking Drug to Vision Loss The Ozempic blindness and vision loss lawsuit is full steam ahead following the July 2024 study indicating huge increases in the risk of NAION for users of semaglutide

3-nucleotidase/nuclease activity allows Leishmania parasites to escape killing by neutrophil extracellular traps

Innate immunity contributes to cochlear adaptive immune responses

Patients allege that the company marketed Trulicity as a safe option for controlling blood sugar levels but failed to warn about the increased risk of serious health issues

The origins and specifications of the mice used in this study are detailed in the Supplemental Methods

Some products may be contaminated or adulterated with substances not disclosed especially those marketed for weight loss